

Announcement of collaboration with three medical corporations  
for development of dendritic cell-based cancer immunotherapy

OncoTherapy Science, Inc. (OTS) and DC Vaccine Consortium (Osaka Cancer Immunotherapy Clinic, Fukuoka General Cancer Clinic, Biothera Clinic) announce that they have agreed to collaborate to develop dendritic cell-based cancer immunotherapy (DC therapy), by epitope peptide vaccines, developed by OTS. These three medical corporations of DC Vaccine Consortium have been conducting and developing DC therapy for various cancer patients for a long time, and OTS has pioneered and conducted development of cancer specific peptide vaccine from various oncoantigens.

OTS and its subsidiary company “Cancer Precision Medicine (CPM)” are regarding cancer immunotherapy, such as oncoantigen and/or neoantigen DC therapy, as a key player in the field of cancer precision medicine in the near future.

(contents)

1. OTS provided non-exclusive licensing of epitope peptide vaccines developed and owned by OTS to DC Vaccine Consortium.
2. OTS provides information necessary for the use or ordering of epitope peptide vaccines to DC Vaccine Consortium.
3. OTS will receive royalties from DC Vaccine Consortium for each peptide.
4. CPM will collaborate with DC Vaccine Consortium to develop neoantigen-prediction method by massively parallel sequencing.
5. CPM will collaborate with DC Vaccine Consortium to develop early diagnosis method for efficacy of immunotherapy by liquid biopsy.